Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Maintenance Chemotherapy vs Observation in Elderly PCNSL (BLOCAGE-01)
NCT02313389Phase 3Unknown
- Sponsor
- Assistance publique - Hôpitaux de Paris
- Start
- Sep 2015
- Primary completion
- Apr 2023
- Modality
- Monoclonal Antibodies, Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of rituximab, methotrexate and temozolomide in primary central nervous system lymphoma (PCNSL) (2 arms), sponsored by Assistance publique - Hôpitaux de Paris. Primary endpoint: Progression Free Survival at 6 years. Status: unknown.
02
Drugs
rituximabmethotrexatetemozolomide
03
Conditions
primary central nervous system lymphoma (PCNSL)
Beyond the preview
Go deeper on NCT02313389.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02313389.